DOCSLIB.ORG

A Study of the Molecular Basis of the Lysosomal Storage Disorder

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Study of the Molecular Basis of the Lysosomal Storage Disorder P\ ■Studies of the Molecular Basis of the Lysosomal Storage Disorder Fucosidosis by Helen Marie Cragg Thesis submitted for the degree of Doctor of Philosophy University of London Division of Biochemistry and Genetics Institute of Child Health ProQuest Number: U541539 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U541539 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Fucosidosis is a rare, autosomal recessive, lysosomal storage disorder resulting from a deficiency of the enzyme a-fucosidase. This defect leads to the accumulation in the lysosomes of tissues and excretion in urine of fucose-containing oligosaccharides, glycoasparagines, and glycolipids. The gene encoding lysosomal a-fucosidase has been mapped to the short arm of chromosome 1 at position lp34.1-36.1 and consists of eight exons spanning 23kb ofDNA. In this thesis the molecular basis of the enzyme defect has been investigated in thirteen fucosidosis patients. The residual a-fucosidase activity in extracts of fibroblasts, leukocytes and plasma has been characterised and the urinary oligosaccharides investigated by thin layer chromatography. Patient DNA was haplotyped using two previously described restriction fragment length polymorphisms observed with the restriction enzymes, PvuQ. and BgH. Single strand conformation polymorphism analysis (SSCP) was used to screen the 13 fucosidosis patients for mutations. 8 of the 9 classic fucosidosis patients revealed conformational alterations (89%). These alterations were subsequently sequenced resulting in eight new mutations being identified. One mutation, P5R, was located in the signal peptide of a-fucosidase. A lObp deletion, G96fs (TAG), resulting in a frame shift and the production of a stop codon was also identified in exon 1. Analysis of exon 3 revealed three frirther mutations, W138X, Y21IX and a Ibp deletion in the donor splice site, S216fs(TGA). A g^a point mutation was found in the highly conserved splice site sequences of intron 5. Exon 6 contained two mutations, a missense point mutation N329Y and a Ibp insertion, Y330fs(TAA), which results in the production of a stop codon. The latter mutation was found in the same patient as the P5R mutation, both were homozygous. A new polymorphism has also been identified in exon 5, Q281R, which has been shown to be responsible for the Ful/Fu2 polymorphism of a-fucosidase isoenzymes observed by starch gel electrophoresis. Transient expression of the normal a-fucosidase cDNA in COS cells was established which allowed the further investigation of the mutations identified. W138X, S216fs(TAG), and both alleles of the polymorphism, Q281R, were created by site directed mutagenesis of normal a- fucosidase cDNA and characterisation of the expressed protein was carried out following transient expression. To Andrew 111 Preface Parts of the work described in this thesis were presented in the following pubhcations; 1) Cragg H, O'Brien J, Kretz K, Willems P, Williamson M, Winchester B (1991) The molecular genetics of fucosidosis. Abst. 15. 8th Workshop of the European Study Group of Lysosomal Storage Disorders (ESGLD), Annecy, France. 2) Cragg H, Grant J, Kretz K, O'Brien J, Willems P, Williamson M, Young E, Winchester B (1992) A splice site mutation in fucosidosis. Abst P212. 30th Annual Symposium of the Society for the study of inborn errors of metabolism (SSIEM) Leuven, Belgium. 3)Wilhamson M, Cragg H, Grant J, Kretz K, O'Brien JS, Willems PJ, Young E, Winchester B (1993) A 5'splice site mutation in fucosidosis. J Med Genet 30:218-223. 4) Cragg H, Winchester B, Seo HC, O'Brien J, Swallow D (1994) Molecular basis of the common electrophoretic polymorphism (Ful/Fu2) in human a-L-fucosidase. J Med Genet 31:8:659-660 5)Vellodi A, Cragg HM, Winchester B, Young E, Young J, Downie CJC, Hoare D, Stocks R, Baneijee GK (in press) Allogeneic Bone Marrow Transplantation for fucosidosis. 6) Cragg H, Winchester B (submitted for publication) Mutation analysis in patients with fucosidosis. IV The experimental work presented in this thesis was all carried out by the candidate with the exception of some of the enzyme assays which were carried out prior to the commencement of the project or as routine by either Magali Williamson or Elisabeth Young, to whom I am very grateful. The Bone marrow transplantation and any related clinical procedures were performed by Dr. Vellodi and his colleagues. My contribution to the BMT study was genetical and some biochemical analysis of the patient before and after the transplantation. Any work included in this thesis that is not my own has been clearly stated and the appropriate colleagues acknowledged. Acknowledgements I would like to thank my supervisor Bryan Winchester for the help and support he has provided through out this project. Many thanks go to all the members of Club 310 (AKA 5022), especially Barbara, David, Jess B and Jess T for all their help, friendship and endless hours of amusement. I would especially like to thank Barbara for both the proof reading of this thesis and her unlimited source of encouragement and fim, an essential addition to any PhD. I would like to thank the numerous clinicians who have provided the patients for this study and Dr Vellodi who has encouraged our involvement in the study of the first bone marrow transplant in fucosidosis. I would also like to thank Richard Jones for volunteering his help and advios which resulted in a more interesting and productive final year. I would like to acknowledge the work and help that has been provided by the clinical biochemistry laboratory, especially Elizabeth Young and Tony Whitfield. I would also like to acknowledge the supply of patients and cDNA probes that were essential to this project by Patrick Willems, John O'Brien and Heo-Chan Seo. Thanks must also go to my family, especially my mother, for all their support and encouragement which they have given me from the beginning to the very end of this project. Thanks also to my father whose own personal battle has provided an endless source of both inspiration and determination which has helped me during this project and will always remain with me. Finally the biggest thanks must go to Andrew for all his help, enthusiasm and support during the last 4 years. Also I would like to thank him for his role as assistant producer of this thesis. V Contents Pagel Title page Abstract i Dedication iii Preface iv Acknowledgements V Contents vi List of figures XV List of tables XX List of abbreviations xxi CHAPTER 1-Introduction 1 1.1 Lysosomes, lysosomal enzymes and lysosomal storage disorders 2 1.1.1 Lysosomes 2 1.1.2 Biosynthesis and processing of lysosomal enzymes 3 1.1.3 Lysosomal catabolism of glycoproteins and glycosphingolipids 7 1.1.3.1 Glycoproteins 7 1.1.3 .2 Glycosphingolipids 7 1.1.4 Lysosomal storage disorders 11 1.2 Fucosidosis 12 1.2.1 Definition 12 1.2.2 History 12 1.2.3 Incidence 13 1.2.4 Clinical features 14 1.2.5 Pathology 16 1.2.6 Diagnosis 16 1.2.7 Treatment 19 1.3 a-Fucosidase 21 1.3.1 Definition 21 1.3.2 Occurrence 21 1.3.3 Substrate specifity 22 VI 1.3.4 Properties of a- fucosidase 22 1.3.4.1 pH optimum 22 1.3.4.2 Michaelis-Menten constant 22 1.3.4.3 The active site of a-fucosidase 22 1.3.5 Biosynthesis and processing | of a-fucosidase 23 1.3.6 Polymorphisms of a- fucosidase 25 1.3 .6.1 Common electrophoretic polymorphism of a-fucosidase 25 1.3 .6.2 Low plasma activity polymorphism 26 1.4 Molecular Genetics 27 1.4.1 Chromosomal localisation 27 1.4.1.1 FUCAl 27 1.4.1.2FUCA1L 28 1.4.1.3FUCA2 28 1.4.2 a-fucosidase cDNA 29 1.4.3 Gene structure 29 1.4.3 .1 Restriction endonuclease mapping of genomic FUCAl 29 1.4.3 .2 Restriction fragment length polymorphisms (RFLP) 3 0 1.4.4 Known mutations in FUCAl 31 1.4.4.1 Obliteration of EcoRl restriction site 31 1.4.4.2 Deletion of the 3' region of FUCAl 32 1.5 Aims of the project 32 CHAPTER 2-Materials and methods 33 2.1 Materials 34 2.2 Solutions and media 35 2.2.1 General solutions 3 5 2.2.2 Sequencing solutions 35 2.2.3 Cycle sequencing solutions 36 2.2.4 Bacterial media 36 2.2.5 Tissue culture solutions 37 2.2.6 Southern blotting and hybridisation solutions 37 VII 2.2.7 Qiagen plasmid preparation solutions 38 2.2.8 Small scale plasmid preparation solutions 38 2.2.9 Solutions for site-directed mutagenesis 38 2.3 Methods 39 2.3.1 Tissue culture 39 2.3.1.1 Tissue culture of fibroblast and COS cell lines 39 2.3.1.2 Sub culturing and harvesting of fibroblasts and COS cells 39 2.3 .1.3 Storage of cells for subsequent reculture 3 9 2.3 .1.4 Storage of fibroblasts for enzyme assay or DNA extraction 39 2 .3 .1.5 Transformation of lymphocytes with Epstein Barr Virus 40 2 .3 .1.6 Culture of lymphoblast cell lines 40 2.3.2 Enzyme studies 41 2.3.2.1 Preparation cells for assay of enzymes 41 2.3.2.2 Assay of a-fucosidase activity 41 2.3.2.3 Assay of p -hexosaminidase activity 41 2.3.2.4 Protein determination 42 2.3.3 Thin layer chromatography of urinary oligosaccharides 42 2.3.4 Extraction and precipitation of DNA 44 2.3.4.1 Extraction of human
Load more

Recommended publications
  • Characterization of Α-L-Fucosidase and Other Digestive Hydrolases From
    Acta Tropica 141 (2015) 118–127 Contents lists available at ScienceDirect Acta Tropica journal homepage: www.elsevier.com/locate/actatropica Characterization of ␣-L-fucosidase and other digestive hydrolases from Biomphalaria glabrata Natalia N. Perrella a,b, Rebeca S. Cantinha c,d, Eliana Nakano c, Adriana R. Lopes a,∗ a Laboratory of Biochemistry and Biophysics—Instituto Butantan, São Paulo, Brazil b Programa de Pós Graduac¸ ão Interunidades em Biotecnologia PPIB, Universidade de São Paulo, São Paulo, SP, Brazil c Laboratory of Parasitology—Instituto Butantan, São Paulo, Brazil d Instituto de Pesquisas Energéticas e Nucleares, Universidade de São Paulo, São Paulo, SP, Brazil article info abstract Article history: Schistosoma mansoni is one of the major agents of the disease Schistosomiasis, which is one of the Received 10 February 2014 major global public health concerns. Biomphalaria glabrata is an obligate intermediate mollusc host of Received in revised form 3 July 2014 S. mansoni. Although the development of S. mansoni occurs in the snail hepatopancreas, studies that Accepted 12 August 2014 focus on this organ remain limited. In this study, we biochemically identified five distinct carbohy- Available online 16 September 2014 drases (amylase, maltase, ␣-glucosidase, trehalase, and ␣-L-fucosidase), lipases, and peptidases in the B. glabrata hepatopancreas and focused on the isolation and characterization of the activity of ␣-L- Keywords: fucosidase. The isolated ␣-L-fucosidase has a molecular mass of 141 kDa, an optimum pH of 5.8, and Hepatopancreas ␣ Enzymes is inhibited by Tris, fucose, and 1-deoxyfuconojirimycin. B. glabrata -L-fucosidase is an exoglycosidase ␮ ␣-L-Fucosidase that can hydrolyze the natural substrate fucoidan to fucose residues.
    [Show full text]
  • Glycoproteomics-Based Signatures for Tumor Subtyping and Clinical Outcome Prediction of High-Grade Serous Ovarian Cancer
    ARTICLE https://doi.org/10.1038/s41467-020-19976-3 OPEN Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer Jianbo Pan 1,2,3, Yingwei Hu1,3, Shisheng Sun 1,3, Lijun Chen1, Michael Schnaubelt1, David Clark1, ✉ Minghui Ao1, Zhen Zhang1, Daniel Chan1, Jiang Qian2 & Hui Zhang 1 1234567890():,; Inter-tumor heterogeneity is a result of genomic, transcriptional, translational, and post- translational molecular features. To investigate the roles of protein glycosylation in the heterogeneity of high-grade serous ovarian carcinoma (HGSC), we perform mass spectrometry-based glycoproteomic characterization of 119 TCGA HGSC tissues. Cluster analysis of intact glycoproteomic profiles delineates 3 major tumor clusters and 5 groups of intact glycopeptides. It also shows a strong relationship between N-glycan structures and tumor molecular subtypes, one example of which being the association of fucosylation with mesenchymal subtype. Further survival analysis reveals that intact glycopeptide signatures of mesenchymal subtype are associated with a poor clinical outcome of HGSC. In addition, we study the expression of mRNAs, proteins, glycosites, and intact glycopeptides, as well as the expression levels of glycosylation enzymes involved in glycoprotein biosynthesis pathways in each tumor. The results show that glycoprotein levels are mainly controlled by the expression of their individual proteins, and, furthermore, that the glycoprotein-modifying glycans cor- respond to the protein levels of glycosylation enzymes. The variation in glycan types further shows coordination to the tumor heterogeneity. Deeper understanding of the glycosylation process and glycosylation production in different subtypes of HGSC may provide important clues for precision medicine and tumor-targeted therapy.
    [Show full text]
  • The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
    Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
    [Show full text]
  • Supplementary Table 2
    Supplementary Table 2. Differentially Expressed Genes following Sham treatment relative to Untreated Controls Fold Change Accession Name Symbol 3 h 12 h NM_013121 CD28 antigen Cd28 12.82 BG665360 FMS-like tyrosine kinase 1 Flt1 9.63 NM_012701 Adrenergic receptor, beta 1 Adrb1 8.24 0.46 U20796 Nuclear receptor subfamily 1, group D, member 2 Nr1d2 7.22 NM_017116 Calpain 2 Capn2 6.41 BE097282 Guanine nucleotide binding protein, alpha 12 Gna12 6.21 NM_053328 Basic helix-loop-helix domain containing, class B2 Bhlhb2 5.79 NM_053831 Guanylate cyclase 2f Gucy2f 5.71 AW251703 Tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 5.57 NM_021691 Twist homolog 2 (Drosophila) Twist2 5.42 NM_133550 Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 4.93 NM_031120 Signal sequence receptor, gamma Ssr3 4.84 NM_053544 Secreted frizzled-related protein 4 Sfrp4 4.73 NM_053910 Pleckstrin homology, Sec7 and coiled/coil domains 1 Pscd1 4.69 BE113233 Suppressor of cytokine signaling 2 Socs2 4.68 NM_053949 Potassium voltage-gated channel, subfamily H (eag- Kcnh2 4.60 related), member 2 NM_017305 Glutamate cysteine ligase, modifier subunit Gclm 4.59 NM_017309 Protein phospatase 3, regulatory subunit B, alpha Ppp3r1 4.54 isoform,type 1 NM_012765 5-hydroxytryptamine (serotonin) receptor 2C Htr2c 4.46 NM_017218 V-erb-b2 erythroblastic leukemia viral oncogene homolog Erbb3 4.42 3 (avian) AW918369 Zinc finger protein 191 Zfp191 4.38 NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 4.38 NM_017020 Interleukin 6 receptor Il6r 4.37 AJ002942
    [Show full text]
  • Selective Loss of Glucocerebrosidase Activity in Sporadic Parkinsonłs
    Chiasserini et al. Molecular Neurodegeneration (2015) 10:15 DOI 10.1186/s13024-015-0010-2 SHORT REPORT Open Access Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies Davide Chiasserini1†, Silvia Paciotti2†, Paolo Eusebi1,3, Emanuele Persichetti2, Anna Tasegian2, Marzena Kurzawa-Akanbi4,5, Patrick F Chinnery4,5, Christopher M Morris6, Paolo Calabresi1,7, Lucilla Parnetti1* and Tommaso Beccari2* Abstract Background: Lysosomal dysfunction is thought to be a prominent feature in the pathogenetic events leading to Parkinson’s disease (PD). This view is supported by the evidence that mutations in GBA gene, coding the lysosomal hydrolase β-glucocerebrosidase (GCase), are a common genetic risk factor for PD. Recently, GCase activity has been shown to be decreased in substantia nigra and in cerebrospinal fluid of patients diagnosed with PD or dementia with Lewy Bodies (DLB). Here we measured the activity of GCase and other endo-lysosomal enzymes in different brain regions (frontal cortex, caudate, hippocampus, substantia nigra, cerebellum) from PD (n = 26), DLB (n = 16) and age-matched control (n = 13) subjects, screened for GBA mutations. The relative changes in GCase gene expression in substantia nigra were also quantified by real-time PCR. The role of potential confounders (age, sex and post-mortem delay) was also determined. Findings: Substantia nigra showed a high activity level for almost all the lysosomal enzymes assessed. GCase activity was significantly decreased in the caudate (−23%) and substantia nigra (−12%) of the PD group; the same trend was observed in DLB. In both groups, a decrease in GCase mRNA was documented in substantia nigra.
    [Show full text]
  • Characterization of Aspartylglucosaminidase Activation and Aspartylglucosaminuria Mutations
    Arto Pennanen Publications of the National Public Health Institute A 1 / 2004 — INDOOR AIR POLLUTION AND HEALTH RISKS IN FINNISH ICE ARENAS RISKSINFINNISHICE AND HEALTH AIR POLLUTION INDOOR Jani Saarela CHARACTERIZATION OF ASPARTYLGLUCOSAMINIDASE ACTIVATION AND ASPARTYLGLUCOSAMINURIA MUTATIONS ISBN 951-740-485-9 ISSN 0359-3584 ISBN 951-740-486-7 (pdf) Department of Molecular Medicine, ISSN 1458-6290 (pdf) National Public Health Institute, Helsinki, Finland and http://www.ktl.fi /portal/suomi/julkaisut/julkaisusarjat/ Department of Medical Genetics, kansanterveyslaitoksen_julkaisuja_a/ University of Helsinki, Finland Kopijyvä Kuopio 2005 Helsinki 2004 PPennanen_kansi.inddennanen_kansi.indd 1 117.2.20057.2.2005 115:26:195:26:19 CHARACTERIZATION OF ASPARTYLGLUCOSAMINIDASE ACTIVATION AND ASPARTYLGLUCOSAMINURIA MUTATIONS Jani Saarela Department of Molecular Medicine, National Public Health Institute, Helsinki, Finland and Department of Medical Genetics, University of Helsinki, Finland Academic Dissertation To be publicly discussed with the permission of the Medical Faculty of the University of Helsinki, in the lecture room 3 of Biomedicum Helsinki, Haartmaninkatu 8, Helsinki, on January 30th, 2004, at 12 o’clock noon. Helsinki 2004 Supervised by Professor Leena Peltonen-Palotie National Public Health Institute and Department of Medical Genetics University of Helsinki, Helsinki, Finland Reviewed by Professor Ole Kristian Tollersrud and Docent Marc Baumann Department of Medical Biochemistry Protein Chemistry/Proteomics Unit University of Tromsoe and Neuroscience Research Program Tromsoe, Norway University of Helsinki, Helsinki, Finland To be publicly discussed with Professor Marja Makarow Institute of Biotechnology and Department of Applied Biochemistry and Molecular Biology University of Helsinki, Helsinki, Finland Julkaisija-Utgivare-Publisher Kansanterveyslaitos (KTL) Mannerheimintie 166 00300 Helsinki puh. vaihde 09-47441, felefax 09-4744 8408 Folkhälsoinstitutet Mannerheimvägen 166 00300, Helsinki tel.
    [Show full text]
  • Survey of Diagnosis of Lysosomal Storage Disorders
    Survey of diagnosis of lysosomal storage disorders Milan Elleder Institute of Inherited Metabolic Disorders Charles University, 1st Faculty of Medicine and University Hospital Prague October 5, 2006 prehistory – empirical part of the story clinical reports by Tay (1881), Gaucher (1882) and Sachs (1896) and by others modern history of the lysosomes their discovery: C. de Duve et al. (Biochem. J. 60, 604, 1955) Nobel Prize 1974 modern history of the lysosomal storage •H.G. Hers et al. (1963) Acid glucosidase deficiency in GSD II •Austin et al. (1963) Arylsulphatase deficiency in MLD present state of the art (2006) – 48 defined entities of different molecular basis (groups Ia,b and II) neuronal lipofuscinosesceroid t r P i a p l e m pt i enzymopathies t i o d y Ca l- y due to mutant GSD II p l r p t o e h te p ep i t enzyme a n i se c d i a id t n at α h a h -1 i s D protein lp o e e u ,4 e s s lysosomal storage -g s I a e te (n=30) d t luc r i ha a n lp os se ro u se disorders Ia β a ida u -s ta -glu ci d -2 fa cos d l se -i te l ylc ip L a -su era ase - on N dase mid α ur an ini MPS ase Id ar sam ep luco n=10 cera h D-g midase c-α- lysosome NA β-galactosylceramidase * expanded by CoA:α-glucosaminide NAc-transferase ase G yelin storage lcNAc- 6-su gom lphate sulph sphin A GalNAc-6-sulphate sulphataseatase lipidoses tase G sulfa alN n=9 aryl β Ac B -g -4- luc sul ase * h ur pha id A ya on te in e lu id su s A * r ase lp m a N o hat d e * a -a n as sa i s id e o e s c c n ase p e a a s s u i e e t e l d e a s d s a y ( -g m i s r l h a a - a d y n a t α β osi i a s i d - t d y - l s u i d c o c i l g r s i a c o A m s g o 2006 N u la s luc la n o l a n i o c g r co c t n - n t a ga u u o c c o - a i n s -β e a d F a s ) α a m c n - l a - M α a m i A - n α M g N α i * - in d - a β β i s glycoproteinoses d e a s n=7 e 29 hydrolases 1 transferase I.A lysosomal enzymopathies caused by mutation of the enzyme protein mutated enzymes degrading lipids, 20.
    [Show full text]
  • Storage Disorders
    GENETIC TESTING SOLUTIONS FOR: STORAGE DISORDERS EGL Genetics has nearly 50 years of genetic testing history built upon a strong academic foundation. Our expertise spans common and rare genetic disease testing, genomic variant interpretation, test development and research. As we have grown, we have evolved into a high-science and high-performing CLIA-certifi ed and CAP-accredited laboratory with over 1,100 test offerings across biochemical genetics, cytogenetics, and molecular genetic testing. COMPREHENSIVE OFFERINGS Lysosomal storage disorders and glycogen storage disorders (GSDs) with numerous subtypes, wide-ranging phenotypes and multi-organ and system involvement, which are often impossible to diagnose based on clinical features alone. EGL Genetics offers disease-specifi c, as well as, comprehensive biochemical and molecular testing to pinpoint the underlying cause of symptoms. Identifi cation of a causative genetic defect may provide information for prognosis and therapeutic intervention, and is required for carrier testing and early prenatal diagnosis. Lysosomal Storage Disorders • Mucopolysaccharidoses • Sphingolipidoses • Oligosaccharidoses Glycogen Storage Disorders ADVANTAGES OF PARTNERING WITH EGL GENETICS: • Board-certifi ed laboratory directors & genetic counselors to answer clinical and analytical questions • EGL Genetics’ oligosaccharide screening method provides additional information and more targeted follow-up pathways than traditional qualitative screens • Customizable NGS panels with add-on genes available upon request
    [Show full text]
  • Structural and Biochemical Insights Into Biosynthesis and Degradation of and Degradation Into Insights Biosynthesis and Biochemical Structural
    Tom Reichenbach Tom kth royal institute of technology Structuralbiochemicaland biosynthesisinsights into degradation and of Doctoral Thesis in Biotechnology Structural and biochemical insights into biosynthesis and degradation of N-glycans TOM REICHENBACH N -glycans ISBN 978-91-7873-660-7 TRITA-CBH-FOU-2020:41 KTH2020 www.kth.se Stockholm, Sweden 2020 Structural and biochemical insights into biosynthesis and degradation of N-glycans TOM REICHENBACH Academic Dissertation which, with due permission of the KTH Royal Institute of Technology, is submitted for public defence for the Degree of Doctor of Philosophy on Friday the 16th October 2020, at 10:00 a.m. in Kollegiesalen, KTH, Brinellvägen 8, Stockholm. Doctoral Thesis in Biotechnology KTH Royal Institute of Technology Stockholm, Sweden 2020 © Tom Reichenbach ISBN 978-91-7873-660-7 TRITA-CBH-FOU-2020:41 Printed by: Universitetsservice US-AB, Sweden 2020 Abstract Carbohydrates are a primary energy source for all living organisms, but importantly, they also participate in a number of life-sustaining biological processes, e.g. cell signaling and cell-wall synthesis. The first part of the thesis examines glycosyltransferases that play a crucial role in the biosynthesis of N-glycans. Precursors to eukaryotic N-glycans are synthesized in the endoplasmic reticulum (ER) in the form of a lipid-bound oligosaccharide, which is then transferred to a nascent protein. The first seven sugar units are assembled on the cytoplasmic side of the ER, which is performed by glycosyltransferases that use nucleotide sugars as donors. The mannosyl transferase PcManGT is produced by the archaeon Pyrobaculum calidifontis, and the biochemical and structural results presented in the thesis suggest that the enzyme may be a counterpart to the glycosyltransferase Alg1 that participates in the biosynthesis of N-glycans in eukaryotes.
    [Show full text]
  • Glucocerebrosidase: Functions in and Beyond the Lysosome
    Journal of Clinical Medicine Review Glucocerebrosidase: Functions in and Beyond the Lysosome Daphne E.C. Boer 1, Jeroen van Smeden 2,3, Joke A. Bouwstra 2 and Johannes M.F.G Aerts 1,* 1 Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Faculty of Science, 2333 CC Leiden, The Netherlands; [email protected] 2 Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Faculty of Science, 2333 CC Leiden, The Netherlands; [email protected] (J.v.S.); [email protected] (J.A.B.) 3 Centre for Human Drug Research, 2333 CL Leiden, The Netherlands * Correspondence: [email protected] Received: 29 January 2020; Accepted: 4 March 2020; Published: 9 March 2020 Abstract: Glucocerebrosidase (GCase) is a retaining β-glucosidase with acid pH optimum metabolizing the glycosphingolipid glucosylceramide (GlcCer) to ceramide and glucose. Inherited deficiency of GCase causes the lysosomal storage disorder named Gaucher disease (GD). In GCase-deficient GD patients the accumulation of GlcCer in lysosomes of tissue macrophages is prominent. Based on the above, the key function of GCase as lysosomal hydrolase is well recognized, however it has become apparent that GCase fulfills in the human body at least one other key function beyond lysosomes. Crucially, GCase generates ceramides from GlcCer molecules in the outer part of the skin, a process essential for optimal skin barrier property and survival. This review covers the functions of GCase in and beyond lysosomes and also pays attention to the increasing insight in hitherto unexpected catalytic versatility of the enzyme. Keywords: glucocerebrosidase; lysosome; glucosylceramide; skin; Gaucher disease 1.
    [Show full text]
  • Characterization of the Regulation of the Er Stress Response by the Dna Repair Enzyme Aag
    DECIPHERING THE CROSSTALK: CHARACTERIZATION OF THE REGULATION OF THE ER STRESS RESPONSE BY THE DNA REPAIR ENZYME AAG Clara Forrer Charlier Faculty of Health and Medical Sciences Department of Biochemistry and Physiology This thesis is submitted for the degree of Doctor of Philosophy June 2018 DECIPHERING THE CROSSTALK: CHARACTERIZATION OF THE REGULATION OF THE ER STRESS RESPONSE BY THE DNA REPAIR ENZYME AAG- Clara Forrer Charlier – June 2018 SUMMARY The genome is a very dynamic store of genetic information and constantly threatened by endogenous and exogenous damaging agents. To maintain fidelity of the information stored, several robust and overlapping repair pathways, such as the Base Excision Repair (BER) pathway, have evolved. The main BER glycosylase responsible for repairing alkylation DNA damage is the alkyladenine DNA glycosylase (AAG). Repair initiated by AAG can lead to accumulation of cytotoxic intermediates. Here, we report the involvement of AAG in the elicitation of the unfolded protein response (UPR), a mechanism triggered to restore proteostasis in the cell whose dysfunction is implicated in diseases like diabetes, Alzheimer’s disease and cancer. Firstly, we determined that not only human ARPE-19 cells were capable of eliciting the UPR, but that an alkylating agent, methyl methanesulfonate (MMS), also triggers the response, and that in the absence of AAG the response is greatly diminished. Our luciferase reporter assay indicates that the response is activated on multiple branches (IRE1 and ATF6) on both AAG-proficient and deficient cells. Although no transcriptional induction of UPR markers was detected by RT-qPCR at 6 hours post MMS treatment, preliminary western-blot data at 6 and 24h, show activation of key UPR markers (p-eIF2α, BiP and XBP-1) upon MMS treatment in wild-type cells and little or no activation on AAG -/-.
    [Show full text]
  • Lgals3bp Cell Adhesion [GO:0007155] Extracellular Matrix [GO:0031012
    Supplementary material Ann Rheum Dis Gene ontology (molecular Gene.NameGene ontology (biological process) Gene ontology (cellular component) function) extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; membrane [GO:0016020]; scavenger receptor activity Lgals3bp cell adhesion [GO:0007155] proteinaceous extracellular matrix [GO:0005578] [GO:0005044] extracellular matrix structural extracellular matrix organization [GO:0030198]; endoplasmic reticulum [GO:0005783]; extracellular constituent [GO:0005201]; hydrogen peroxide catabolic process [GO:0042744]; matrix [GO:0031012]; extracellular space heme binding [GO:0020037]; oxidation-reduction process [GO:0055114]; [GO:0005615]; proteinaceous extracellular matrix metal ion binding [GO:0046872]; Pxdn response to oxidative stress [GO:0006979] [GO:0005578] peroxidase activity carbohydrate biosynthetic process [GO:0016051]; N-acetylgalactosamine 4-O- dermatan sulfate proteoglycan metabolic process Golgi membrane [GO:0000139]; integral component sulfotransferase activity Chst14 [GO:0050655] of membrane [GO:0016021] [GO:0001537] cell-cell adhesion [GO:0098609]; cell migration [GO:0016477]; cell recognition [GO:0008037]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; homophilic cell adhesion via plasma membrane adhesion cell adhesion molecule binding molecules [GO:0007156]; positive regulation of [GO:0050839]; dynein light chain natural killer cell mediated cytotoxicity directed binding [GO:0045503]; protein
    [Show full text]